When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ACRS - Aclaris Is Worth A Look After Positive Data And Strategic Review Potential
Aclaris Therapeutics Inc.
Aclaris Therapeutics (ACRS) announced that it had obtained positive resultsfor its phase 2 study using ATI-501 to treat patients with Alopecia areata. The trial met the primary and secondary endpoint of the study. I believe this creates a great buying opportunity because there are a lot more catalysts that are expected in the second half of 2019. Most notably are two phase 3 studies using A-101 to treat common warts, which are expected to be released in the secone half of 2019. The pipeline is huge and there are still multiple shots